- Home
- MGTX
as 05-30-2025 4:00pm EST
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 515.7M | IPO Year: | N/A |
| Target Price: | $24.00 | AVG Volume (30 days): | 658.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.85 - $8.75 | Next Earning Date: | 05-13-2025 |
| Revenue: | $34,508,000 | Revenue Growth: | 203.23% |
| Revenue Growth (this year): | 382.62% | Revenue Growth (next year): | 66.88% |
Stock Insider Trading Activity of MeiraGTx Holdings plc (MGTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Giroux Richard | MGTX | CFO & COO | Apr 22 '25 | Sell | $6.00 | 24,000 | $144,000.00 | 882,494 | |
| Forbes Alexandria | MGTX | PRESIDENT & CEO | Apr 8 '25 | Sell | $5.34 | 47,500 | $253,650.00 | 1,408,983 |
Latest MeiraGTx Holdings plc News
MGTX Breaking Stock News: Dive into MGTX Ticker-Specific Updates for Smart Investing
MT Newswires
18 days ago
Chardan Adjusts MeiraGTx Price Target to $35 From $38, Maintains Buy Rating
GlobeNewswire
18 days ago
MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting
Zacks
19 days ago
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates
GlobeNewswire
19 days ago
MeiraGTx Reports First Quarter 2025 Financial and Operational Results
MT Newswires
22 days ago
Sector Update: Health Care Stocks Softer Friday Afternoon
MT Newswires
23 days ago
MeiraGTx Says FDA Granted RMAT Designation to AAV-GAD for Treating Parkinson's; Shares Up Pre-Bell
GlobeNewswire
23 days ago
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease
MT Newswires
a month ago
Top Premarket Decliners
Compare MGTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MGTX MeiraGTx Holdings plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.